AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Gastrointestinal Parasites: Morantel tartrate is effective against various species of gastrointestinal nematodes, including roundworms such as Haemonchus contortus, Teladorsagia circumcincta, Trichostrongylus spp., and Oesophagostomum spp. It works by interfering with the nervous system of the parasites, causing paralysis and expulsion from the host animal's gastrointestinal tract.
Broad-Spectrum Activity: Morantel tartrate has broad-spectrum activity against both adult and larval stages of gastrointestinal nematodes. It is effective against both susceptible and some resistant strains of parasites, making it a valuable tool in parasite control programs for livestock.
Sheep and Goat Parasitism: Morantel tartrate is commonly used in sheep and goats to treat and control infections with gastrointestinal nematodes, which can cause weight loss, poor growth, anemia, diarrhea, and other symptoms in affected animals. Regular deworming with morantel tartrate can help prevent parasitic infestations and improve overall animal health and productivity.
Horse Parasitism: Morantel tartrate is also used in horses to treat and control infections with gastrointestinal parasites such as large and small strongyles, as well as pinworms. Regular deworming with morantel tartrate can help prevent parasitic-related health issues in horses, including colic, weight loss, and poor coat condition.
Safety and Tolerability: Morantel tartrate is generally safe and well-tolerated when used as directed. However, overdosing or misuse of the medication can lead to adverse effects such as gastrointestinal upset, including diarrhea and colic. It's essential to follow the dosage instructions provided by a veterinarian and to accurately estimate the weight of the animal being treated.
Resistance Management: Like other anthelmintic medications, resistance to morantel tartrate can develop in parasite populations over time with frequent and indiscriminate use. To minimize the risk of resistance, veterinarians may recommend implementing strategic deworming programs, rotating between different classes of anthelmintics, and conducting fecal egg count tests to monitor parasite burdens and drug efficacy.
Contraindications: Morantel tartrate should not be used in animals with known hypersensitivity to the drug or in animals intended for human consumption if the withdrawal period has not been observed. Pregnant and lactating animals should be treated with caution, and veterinary guidance should be sought before administering morantel tartrate to these animals.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0 | 0 | |
| ADHD | 0.3 | -0.3 | |
| Allergic Rhinitis (Hay Fever) | 0.5 | 0.5 | |
| Allergies | 0.8 | 0.8 | |
| Alzheimer's disease | 0.8 | 0 | 0 |
| Ankylosing spondylitis | 0.5 | -0.5 | |
| Asthma | 0.6 | 0.6 | |
| Autism | 1.4 | 1.4 | |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 0.3 | 0.3 | 0 |
| Cancer (General) | 0.5 | -0.5 | |
| Carcinoma | 0.3 | 0.3 | |
| Chronic Fatigue Syndrome | 1.4 | 1.4 | |
| Chronic Kidney Disease | 0.8 | 0 | 0 |
| Cognitive Function | 0.6 | 0.6 | |
| Colorectal Cancer | 0.6 | 0.6 | |
| Coronary artery disease | 0.5 | 0.5 | |
| COVID-19 | 1 | 0.9 | 0.11 |
| Crohn's Disease | 0.8 | 0.8 | |
| Depression | 1.5 | 0.5 | 2 |
| Eczema | 0.5 | 0.5 | |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 0.4 | 0.4 | |
| Functional constipation / chronic idiopathic constipation | 0 | 0 | |
| gallstone disease (gsd) | 0.5 | 0.5 | |
| Generalized anxiety disorder | 0.8 | 0.8 | |
| Hashimoto's thyroiditis | 0 | 0 | 0 |
| Heart Failure | 0.5 | 0.5 | |
| hypertension (High Blood Pressure | 0 | 0 | |
| Hypothyroidism | 0.3 | -0.3 | |
| IgA nephropathy (IgAN) | 0.3 | 0.5 | -0.67 |
| Inflammatory Bowel Disease | 1.6 | 1.6 | |
| Intelligence | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 0.5 | 0.5 | |
| Liver Cirrhosis | 0.3 | 0.3 | |
| Long COVID | 0.9 | 0.9 | |
| ME/CFS without IBS | 1.4 | 1.4 | |
| Metabolic Syndrome | 0.8 | 0.8 | |
| Mood Disorders | 1.4 | 0.8 | 0.75 |
| Multiple Sclerosis | 0.9 | 0.9 | |
| neuropathic pain | 0.3 | 0.3 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.1 | |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | |
| Obesity | 0.5 | 1.3 | -1.6 |
| obsessive-compulsive disorder | 0.5 | -0.5 | |
| Osteoarthritis | 0.6 | 0.6 | |
| Osteoporosis | 0.3 | 0.3 | |
| Parkinson's Disease | 0.3 | 0.7 | -1.33 |
| Polycystic ovary syndrome | 0.5 | 0.5 | |
| Primary sclerosing cholangitis | 0.5 | -0.5 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.8 | 0.8 | |
| Rosacea | 0 | 0 | |
| Schizophrenia | 0.3 | 0.3 | |
| Sleep Apnea | 0.3 | -0.3 | |
| Stress / posttraumatic stress disorder | 0.6 | -0.6 | |
| Systemic Lupus Erythematosus | 0.8 | 0.1 | 7 |
| Type 2 Diabetes | 0.8 | 0 | 0 |
| Ulcerative colitis | 0.2 | 0.2 | |
| Unhealthy Ageing | 0.8 | 0.8 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
